| Literature DB >> 30669445 |
Diego Tesauro1, Antonella Accardo2, Carlo Diaferia3, Vittoria Milano4,5, Jean Guillon6, Luisa Ronga7, Filomena Rossi8.
Abstract
Entities:
Keywords: active targeting receptors; binding peptides; diphenylalanine; drug delivery; peptide; peptide backbone structures; peptide self-assembling carriers
Mesh:
Substances:
Year: 2019 PMID: 30669445 PMCID: PMC6359574 DOI: 10.3390/molecules24020351
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Different classes of peptides can be arrange in supramolecular structures handling the self-assembling phenomena. Various morphologies can be generated according to the rational design of the primary sequence.
Figure 2Diphenylalanine based aggregates can be applied with different biotechnological scopes, producing drug delivery systems, hydrogels matrices, supramolecular contrast agents, and fluorescent aggregates. Chemical and functional decorations (like sequences modification, incorporation of fluorescent dyes and conjugation with chelating agents and polymers) at N- and C-terminus of the primary sequence produce innovative nanostructurated tools.
Figure 3Schematic representation of two approaches used for the synthesis of peptide containing liposomes. In route I (pre-liposomal functionalization) a PA is inserted directly during the liposome formulation. In route II (post-liposomal functionalization) a peptide is anchored on the exteral surfaces after liposome formulation by a selective reaction between two functional groups displayed on the peptide and on the liposome, respectively.
Supramolecular systems decorated with homing peptides able to selectively recognize integrin receptors or membrane receptors belonging to the GPCR superfamily. The bioactive peptide, the peptide conjugation, the encapsulated API, and the corresponding references are reported.
| Receptor | Peptide Sequence | Peptide Derivative | Drug | Ref. |
|---|---|---|---|---|
| Integrin receptor Avβ3 | c(RGDfK) | c(RGDfK)-NHS-PEG-PLA | CA4 | [ |
| c(RGDfK) | c(RGDfK)-SH post liposome modification | CDDP | [ | |
| c(RGDfC) | MBPE-c(RGDfC) post-insertion | DOX | [ | |
| c(RGDf[N-Met]K) | c(RGDf[N-Met]K(Ac-SCH2CO)) | DOX | [ | |
| c(RGDyK) | DSPE-PEG- c(RGDyK) | CDDP | [ | |
| cAbaRGD | DSPE-PEG-cAbaRGD | DOX | [ | |
| iRGD | iRGD-HES-SS-C18 NCs | DOX/sorafenib | [ | |
| G-Protein coupled receptor | Octreotide | OCA-DOTA/ OCA-DTPAGlu | Gd-complex | [ |
| Octreotide | (C18)2(AdOO)5OCT | Gd-complex | [ | |
| Octreotide | (C18)2(AdOO)5OCT | CDDP/DOX | [ | |
| Octreotide | OCT-(PTX)-PEG-b-PCL | PTX | [ | |
| Octreotide | Oct-Phe-PEG-SA | DOX | [ | |
| Octreotide | H40-PLA-PEG-OCT | TDP-A | [ | |
| Octreotide | SAMA-TOC post liposome modification | 111In-DTPA | [ | |
| Octreotide | HSPE-PEG4000-OCT | DOX | [ | |
| [Tyr3]-Octreotate | Maleimido-TATE | 64Cu-DOTA | [ | |
| KE108 | KE108 post micelle modification via NHS | TDP-A | [ | |
| [7–14]BN wild-type | (C18)2-L5-[7–14]BN | 111In-DOTA | [ | |
| [7–14]BN-AA1 analogue | MonY-BN-AA1 | DOX | [ | |
| CCK8 | (C18)2-L5CCK8 | Gd-DOTA/Gd-DTPA | [ |
Figure 4Structure of targeting peptide sequences: (a) c(RGDfK); (b) Otreotide[c(2–7)-FCFWKTCTol]; (c) [7–14]-Bombesin (H-QWAVGHLM-NH2), and (d) CCK8(H-DYMGWMDF-NH2).